240 related articles for article (PubMed ID: 7994789)
1. A phase II study of prophylactic intravesical chemotherapy with epirubicin in the treatment of superficial bladder cancer. Tokyo Women's Medical College Bladder Cancer Collaborating Group.
Ryoji O; Toma H; Nakazawa H; Goya N; Okumura T; Sonoda T; Kihara T; Tanabe K; Onizuka S; Tomoe H
Cancer Chemother Pharmacol; 1994; 35 Suppl():S60-4. PubMed ID: 7994789
[TBL] [Abstract][Full Text] [Related]
2. The effects of intravesical chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin for prophylaxis of recurrence of superficial bladder cancer: a preliminary report.
Uekado Y; Hirano A; Shinka T; Ohkawa T
Cancer Chemother Pharmacol; 1994; 35 Suppl():S65-8. PubMed ID: 7994790
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of early intravesical instillation of epirubicin in superficial bladder cancer. The Nagoya University Urological Oncology Group.
Okamura K; Murase T; Obata K; Ohshima S; Ono Y; Sakata T; Hasegawa Y; Shimoji T; Miyake K
Cancer Chemother Pharmacol; 1994; 35 Suppl():S31-5. PubMed ID: 7994783
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of prophylactic intravesical chemotherapy with 4'-epirubicin in recurrent superficial bladder cancer: comparison of 4'-epirubicin and adriamycin.
Shuin T; Kubota Y; Noguchi S; Hosaka M; Miura T; Kondo I; Fukushima S; Ishizuka E; Furuhata A; Moriyama M
Cancer Chemother Pharmacol; 1994; 35 Suppl():S52-6. PubMed ID: 7994787
[TBL] [Abstract][Full Text] [Related]
5. [Intravesical instillation of epirubicin in the prophylactic treatment of recurrent superficial bladder cancer].
Kobayashi M; Sugaya Y; Yuzawa M; Morita T; Kobayashi Y; Tokue A
Hinyokika Kiyo; 1998 Dec; 44(12):861-4. PubMed ID: 10028430
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of intravesical chemoprophylaxis of epirubicin after transurethral resection of bladder tumors. Tottori University Oncology Group.
Watanabe N; Miyagawa I; Higasibori Y; Nakahara T; Sumi F; Ishida G; Abe B; Inoue A; Hanamoto N
Cancer Chemother Pharmacol; 1994; 35 Suppl():S57-9. PubMed ID: 7994788
[TBL] [Abstract][Full Text] [Related]
7. Effect of prophylactic treatment with intravesical epirubicin on recurrence of superficial bladder cancer--The 6th Trial of the Japanese Urological Cancer Research Group (JUCRG): a randomized trial of intravesical epirubicin at dose of 20mg/40ml, 30mg/40ml, 40mg/40ml.
Kuroda M; Niijima T; Kotake T; Akaza H; Hinotsu S;
Eur Urol; 2004 May; 45(5):600-5. PubMed ID: 15082202
[TBL] [Abstract][Full Text] [Related]
8. A controlled study of intravesical epirubicin with or without alpha 2b-interferon as prophylaxis for recurrent superficial transitional cell carcinoma of the bladder. Finnish Multicentre Study Group.
Raitanen MP; Lukkarinen O
Br J Urol; 1995 Dec; 76(6):697-701. PubMed ID: 8535711
[TBL] [Abstract][Full Text] [Related]
9. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
[TBL] [Abstract][Full Text] [Related]
10. Intravesical combined chemoimmunotherapy with epirubicin and bacillus Calmette-Guérin is not indicated for superficial bladder cancer.
Tozawa K; Okamura T; Sasaki S; Kawai N; Ito Y; Hayashi Y; Kohri K
Urol Int; 2001; 67(4):289-92. PubMed ID: 11741130
[TBL] [Abstract][Full Text] [Related]
11. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
12. Transurethral resection with perioperative instilation on interferon-alpha or epirubicin for the prophylaxis of recurrent primary superficial bladder cancer: a prospective randomized multicenter study--Finnbladder III.
Rajala P; Liukkonen T; Raitanen M; Rintala E; Kaasinen E; Helle M; Lukkarinen O
J Urol; 1999 Apr; 161(4):1133-5; discussion 1135-6. PubMed ID: 10081854
[TBL] [Abstract][Full Text] [Related]
13. Conservative treatment of high grade superficial bladder tumours.
Trinchieri A; Bonacina P; Butti A; Cappoli S; Esposito N; Invernizzi S; Librizzi A; Locatelli G
Arch Ital Urol Androl; 2005 Dec; 77(4):215-8. PubMed ID: 16444936
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the prophylactic usefulness of epirubicin and doxorubicin in the treatment of superficial bladder cancer by intravesical instillation: a multicenter randomized trial. Kobe University Urological Oncology Group.
Eto H; Oka Y; Ueno K; Nakamura I; Yoshimura K; Arakawa S; Kamidono S; Obe S; Ogawa T; Hamami G
Cancer Chemother Pharmacol; 1994; 35 Suppl():S46-51. PubMed ID: 7994786
[TBL] [Abstract][Full Text] [Related]
15. Comparing intra-arterial chemotherapy combined with intravesical chemotherapy versus intravesical chemotherapy alone: a randomised prospective pilot study for T1G3 bladder transitional cell carcinoma after bladder-preserving surgery.
Chen J; Yao Z; Qiu S; Chen L; Wang Y; Yang J; Li J
Cardiovasc Intervent Radiol; 2013 Dec; 36(6):1521-1526. PubMed ID: 23511989
[TBL] [Abstract][Full Text] [Related]
16. Two instillations of epirubicin as prophylaxis for recurrence after transurethral resection of Ta and T1 transitional cell bladder cancer: a prospective, randomized controlled study.
Saika T; Tsushima T; Nasu Y; Miyaji Y; Saegusa M; Takeda K; Kumon H
World J Urol; 2010 Aug; 28(4):413-8. PubMed ID: 20054553
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic chemotherapy with anthracyclines (adriamycin, epirubicin, and pirarubicin) for primary superficial bladder cancer. The Hokkaido University Bladder Cancer Collaborative Group.
Shinohara N; Nonomura K; Tanaka M; Nagamori S; Takakura F; Seki T; Koyanagi T; Togashi M; Maru A
Cancer Chemother Pharmacol; 1994; 35 Suppl():S41-5. PubMed ID: 7994785
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical instillation with epirubicin as a prophylactic treatment for superficial bladder cancer--using two different schedules].
Segawa N; Nishida T; Takahara K; Nomi H; Azuma H; Katsuoka Y
Hinyokika Kiyo; 2008 Nov; 54(11):711-6. PubMed ID: 19068724
[TBL] [Abstract][Full Text] [Related]
19. Results of conservative treatment (transurethral resection plus adjuvant intravesical chemotherapy) in patients with primary T1, G3 transitional cell carcinoma of the bladder.
Serretta V; Piazza S; Pavone C; Piazza B; Pavone-Macaluso M
Urology; 1996 May; 47(5):647-51. PubMed ID: 8650860
[TBL] [Abstract][Full Text] [Related]
20. Delayed high-dose intravesical epirubicin therapy of superficial bladder cancer. A way to reduce the side effects and increase the efficacy--a phase 2 trial.
Bassi P; Spinadin R; Longo F; Saraeb S; Pappagallo GL; Zattoni F; Pagano F
Urol Int; 2002; 68(4):216-9. PubMed ID: 12053020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]